Literature DB >> 29143348

RUNX-2, OPN and OCN expression induced by grey and white mineral trioxide aggregate in normal and hypertensive rats.

C M Martins1,2, I O de Azevedo Queiroz3, E Ervolino3, L T A Cintra3, J E Gomes-Filho3.   

Abstract

AIM: To investigate whether hypertension affects mineralization associated with white and grey mineral trioxide aggregate (MTA Angelus® ) implanted subcutaneously into rats by assaying osteoblastic biomarkers.
METHODOLOGY: Polyethylene tubes containing grey MTA Angelus® , white MTA Angelus® , intermediate restorative material (IRM; positive control) or an empty tube (negative control) were implanted into the dorsal connective tissue of spontaneous hypertensive (n = 12) and Wistar (normotensive; n = 10) rats. Half of the rats in each group were killed after 7 days, and the remaining after 30 days. Tubes with surrounding tissue were removed, and immunostaining was performed to detect RUNX-2, OPN and OCN proteins. The normality of data was analysed using the Shapiro-Wilk test. Comparison of two independent groups was performed using the Mann-Whitney U-test, to detect a significant difference. A post hoc test accounting for multiple comparisons was performed following Tukey's test (P < 0.05).
RESULTS: Under hypertensive conditions after 30 days, both MTA materials were associated with immunolabelling for RUNX-2 from low to moderate, which was less than that observed at normal blood pressure and the 7-day groups (P < 0.05). The expression of OPN and OCN proteins under both MTA conditions was considered low after both 7 and 30 days for the hypertensive condition, and was less than that in animals with normal blood pressure after 30 days (P < 0.05). No immunostaining for any biomarkers in the control and IRM groups was observed (P < 0.05).
CONCLUSION: Hypertension decreased the immunostaining of RUNX-2, OPN and OCN biomarkers in response to MTA. Thus, hypertension can jeopardize the mineralization ability of MTA and may have a negative impact on endodontic treatment outcomes.
© 2017 International Endodontic Journal. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  calcification; hypertension; mineral trioxide aggregate; periapical diseases

Mesh:

Substances:

Year:  2017        PMID: 29143348     DOI: 10.1111/iej.12876

Source DB:  PubMed          Journal:  Int Endod J        ISSN: 0143-2885            Impact factor:   5.264


  5 in total

Review 1.  Evolution of endodontic medicine: a critical narrative review of the interrelationship between endodontics and systemic pathological conditions.

Authors:  Luciano Tavares Angelo Cintra; Maximiliano Schünke Gomes; Cristiane Cantiga da Silva; Flávio Duarte Faria; Francine Benetti; Leopoldo Cosme-Silva; Renata Oliveira Samuel; Tiago Novaes Pinheiro; Carlos Estrela; Alvaro Cruz González; Juan José Segura-Egea
Journal:  Odontology       Date:  2021-07-08       Impact factor: 2.634

2.  Neohesperidin promotes the osteogenic differentiation of human bone marrow stromal cells by inhibiting the histone modifications of lncRNA SNHG1.

Authors:  Chuanxin Zhang; Shuai Yuan; Yi Chen; Bo Wang
Journal:  Cell Cycle       Date:  2021-08-30       Impact factor: 5.173

3.  HIF1α Promotes BMP9-Mediated Osteoblastic Differentiation and Vascularization by Interacting with CBFA1.

Authors:  Yuwan Li; Ziming Liu; Hong-De Wang; Jun Zhang; Miaoyuan Lin; Jianye Yang; Jiaxing Huang; Wenqiang Yan; Yingfang Ao
Journal:  Biomed Res Int       Date:  2022-10-01       Impact factor: 3.246

4.  MicroRNA-142 regulates osteoblast differentiation and apoptosis of mouse pre-osteoblast cells by targeting bone morphogenetic protein 2.

Authors:  Bing Luo; Jiafu Yang; Yi Yuan; Pandeng Hao; Xiaoyan Cheng
Journal:  FEBS Open Bio       Date:  2020-07-31       Impact factor: 2.693

5.  Fibrin, Bone Marrow Cells and Macrophages Interactively Modulate Cardiomyoblast Fate.

Authors:  Inês Borrego; Aurélien Frobert; Guillaume Ajalbert; Jérémy Valentin; Cyrielle Kaltenrieder; Benoît Fellay; Michael Stumpe; Stéphane Cook; Joern Dengjel; Marie-Noëlle Giraud
Journal:  Biomedicines       Date:  2022-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.